Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Enhabit Inc. (EHAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: EHAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.98% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 443.72M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 374711 | Beta 1.36 | 52 Weeks Range 6.85 - 11.35 | Updated Date 04/1/2025 |
52 Weeks Range 6.85 - 11.35 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When Before Market | Estimate 0.0549 | Actual 0.04 |
Profitability
Profit Margin -15.1% | Operating Margin (TTM) 4.88% |
Management Effectiveness
Return on Assets (TTM) 2.19% | Return on Equity (TTM) -24.53% |
Valuation
Trailing PE - | Forward PE 23.87 | Enterprise Value 984818769 | Price to Sales(TTM) 0.43 |
Enterprise Value 984818769 | Price to Sales(TTM) 0.43 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA 14.43 | Shares Outstanding 50480000 | Shares Floating 39397583 |
Shares Outstanding 50480000 | Shares Floating 39397583 | ||
Percent Insiders 3.23 | Percent Institutions 102.52 |
Analyst Ratings
Rating 3.33 | Target Price 8.9 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enhabit Inc.
Company Overview
History and Background
Enhabit, Inc. (formerly Encompass Health Home Health and Hospice) spun off from Encompass Health Corporation in July 2022. Focuses on providing home health and hospice services.
Core Business Areas
- Home Health: Provides skilled nursing, therapy services, and other healthcare services to patients in their homes. Addresses chronic conditions, injury recovery, and post-acute care.
- Hospice: Offers end-of-life care, including pain management, emotional and spiritual support, and respite care for families. Addresses patients with a terminal illness.
Leadership and Structure
Barbara Jacobsmeyer is the CEO. The company is structured around regional and local operational teams reporting to the corporate office.
Top Products and Market Share
Key Offerings
- Home Health Services: Includes skilled nursing, physical therapy, occupational therapy, speech therapy, medical social services, and home health aide services. No definitive market share data readily available, but the home health market is fragmented. Competitors include Amedisys, LHC Group (now part of Optum), and smaller regional and local providers. The industry is estimated in 2024 to be $136.7 billion.
- Hospice Services: Encompasses pain management, symptom control, emotional and spiritual support, and bereavement services. Similarly, market share data is not easily obtained, and the hospice market is also fragmented. Competitors are the same as home health care. The industry is estimated in 2024 to be $41.5 billion.
Market Dynamics
Industry Overview
The home health and hospice industry is driven by an aging population, increasing prevalence of chronic diseases, and a shift towards value-based care. Demand is increasing for home-based care as patients seek more convenient and cost-effective alternatives to institutional settings.
Positioning
Enhabit is a large provider in a fragmented market. Its competitive advantages include its scale, brand recognition (though relatively new as Enhabit), and established relationships with referral sources. Competitors are the same as those mentioned above.
Total Addressable Market (TAM)
Estimated Total Addressable Market (TAM) for home health and hospice is $178.2 billion. Given Enhabit's revenue, it captures a relatively small portion of this TAM, leaving room for growth. Enhabit is positioned to increase this portion with new technologies in the market.
Upturn SWOT Analysis
Strengths
- Large-scale operations
- Established network of referral sources
- Experienced management team
- Strong focus on clinical quality
- Reputation for customer service
Weaknesses
- High labor costs
- Dependence on government reimbursement
- Regulatory compliance challenges
- Newly established brand (Enhabit)
- Competition in a fragmented market
Opportunities
- Growing demand for home-based care
- Expansion into new geographic markets
- Development of new service lines
- Acquisition of smaller providers
- Technological advancements in telehealth
Threats
- Changes in government reimbursement policies
- Increased competition
- Labor shortages
- Rising operating costs
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- AMED (Amedisys Inc)
- LHCG (Optum/LHC Group)
- Chemed Corp (CHE)
Competitive Landscape
Enhabit competes in a fragmented market with several large national players and many smaller regional and local providers. Advantages include large-scale operations and established referral networks. Disadvantages include higher labor costs, reliance on government reimbursement, and regulatory compliance challenges compared to smaller companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth needs to be calculated based on revenue growth, expansion into new markets, and acquisitions. Placeholder only: [2021 Growth, 2022 Growth, 2023 Growth]
Future Projections: Future projections depend on analyst estimates and company guidance, which require up to date research of the market.
Recent Initiatives: Recent initiatives include focusing on telehealth offerings, expanding its geographical footprint, and partnering with payers to drive value-based care arrangements.
Summary
Enhabit is a relatively new standalone company operating in the growing home health and hospice industry. Its large scale and established referral networks are advantages, but it faces challenges from high labor costs and regulatory pressures. The company's growth trajectory will depend on its ability to capitalize on the increasing demand for home-based care and execute its strategic initiatives. Investors should monitor government policy and the fragmented competition.
Similar Companies
- AMED
- LHCG
- CHE
- OTLY (Oatly Group AB)
- TDOC (Teladoc Health, Inc.)
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports (e.g., Home Health Care News, Hospice News)
- Analyst Reports
- Company Investor Relations Website
- CMS.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share and financial data may be estimates. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enhabit Inc.
Exchange NYSE | Headquaters Dallas, TX, United States | ||
IPO Launch date 2022-07-01 | President, CEO & Director Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 10700 | Website https://www.ehab.com |
Full time employees 10700 | Website https://www.ehab.com | ||
Enhabit, Inc. provides home health and hospice services in the United States. The company's home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. It also provides hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.